Ameloblastoma causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2], Simrat Sarai, M.D. [3]

Overview

There are no established causes for ameloblastoma. It is thought that ameloblastoma may be the result of either decreased expression of matrix metalloproteinase-2 which helps in inhibition of the local invasiveness of ameloblastoma, or it is may be due to increased expression of α5β1 integrin which participate in the local invasiveness of ameloblastoma.

Causes

Common Causes

Common causes of ameloblastoma may include:^[1]^[2]

Decreased expression of of matrix metalloproteinase-2
Increased expression α5β1 integrin

Less Common Causes

Less common causes of ameloblastoma may include:^[2]

Mouth or jaw injury
Infections
Inflammation
Diet lacks in protein or minerals

Genetic Causes

Ameloblastoma is caused by a mutation in the FGFR2-RAS-BRAF V600E gene.^[3]^[4]

References

↑ Jeddy, Nadeem; Jeeva, Sathiya; Jeyapradha, T; Lakshmipathy, P; Saikrishna, P; Ananthalakshmi, R (2013). “The molecular and genetic aspects in the pathogenesis and treatment of ameloblastoma”. Journal of Dr. NTR University of Health Sciences. 2 (3): 157. doi:10.4103/2277-8632.117179. ISSN 2277-8632.
↑ ^2.0 ^2.1 Masthan KM, Anitha N, Krupaa J, Manikkam S (April 2015). “Ameloblastoma”. J Pharm Bioallied Sci. 7 (Suppl 1): S167–70. doi:10.4103/0975-7406.155891. PMC 4439660. PMID 26015700.
↑ Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL (November 2014). “Activating FGFR2-RAS-BRAF mutations in ameloblastoma”. Clin. Cancer Res. 20 (21): 5517–26. doi:10.1158/1078-0432.CCR-14-1069. PMID 24993163.
↑ Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K (April 2014). “High frequency of BRAF V600E mutations in ameloblastoma”. J. Pathol. 232 (5): 492–8. doi:10.1002/path.4317. PMC 4255689. PMID 24374844.

Template:WH Template:WS

[JeddyJeeva2013-1] Jeddy, Nadeem; Jeeva, Sathiya; Jeyapradha, T; Lakshmipathy, P; Saikrishna, P; Ananthalakshmi, R (2013). “The molecular and genetic aspects in the pathogenesis and treatment of ameloblastoma”. Journal of Dr. NTR University of Health Sciences. 2 (3): 157. doi:10.4103/2277-8632.117179. ISSN 2277-8632.

[pmid26015700-2] 2.0 ^2.1 Masthan KM, Anitha N, Krupaa J, Manikkam S (April 2015). “Ameloblastoma”. J Pharm Bioallied Sci. 7 (Suppl 1): S167–70. doi:10.4103/0975-7406.155891. PMC 4439660. PMID 26015700.

[pmid24993163-3] Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL (November 2014). “Activating FGFR2-RAS-BRAF mutations in ameloblastoma”. Clin. Cancer Res. 20 (21): 5517–26. doi:10.1158/1078-0432.CCR-14-1069. PMID 24993163.

[pmid24374844-4] Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K (April 2014). “High frequency of BRAF V600E mutations in ameloblastoma”. J. Pathol. 232 (5): 492–8. doi:10.1002/path.4317. PMC 4255689. PMID 24374844.

[1]

[2]

[3]

[4]